• Doxorubicin: Strategic Integration for Translational Impact

  2026-07-07

  This thought-leadership article examines the mechanistic sophistication and translational potential of Doxorubicin (Adriamycin) as a chemotherapeutic agent for solid tumors and hematologic malignancy research. Drawing upon recent advances in mitigating cardiotoxicity, the discussion bridges foundational molecular insight, emerging preclinical strategies, and guidance for researchers aiming to maximize both scientific rigor and clinical relevance. APExBIO’s validated Doxorubicin is spotlighted as a benchmark tool, with actionable protocol parameters and a future-focused outlook framing its evolving role in cancer biology.

• Nascent Cone Precursors as the Cellular Origin of Retinoblas

  2026-07-07

  This study leverages human retinal organoids to uncover that ATOH7+/RXRγ+ nascent cone precursors are the earliest cell-of-origin for retinoblastoma following RB1 loss. The longitudinal analysis of cell state transitions advances understanding of tumor initiation and informs strategies for targeted therapeutic development.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Researc

  2026-07-06

  Masitinib (AB1010) is a highly selective tyrosine kinase inhibitor for targeted inhibition of KIT, PDGFRα, and PDGFRβ in preclinical cancer, mastocytosis, and inflammatory disease research. It is optimized for DMSO-based protocols and is not appropriate in workflows requiring water or ethanol solubility, or broad-spectrum kinase inhibition.

• Doxorubicin in Research: Overcoming ABCG2-Mediated Resistanc

  2026-07-06

  Explore the advanced scientific mechanisms of Doxorubicin, also known as Adriamycin, with a focus on overcoming multidrug resistance in cancer research. This article offers a unique perspective on assay optimization and resistance modulation, grounded in the latest transporter research.

• Applied Use of Z-WEHD-FMK in Inflammation and Pyroptosis Ass

  2026-07-05

  Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) enables precise and irreversible inhibition of inflammatory caspases, empowering researchers to dissect caspase-driven signaling in cell biology and infectious disease models. This article translates recent mechanistic insights into actionable workflows, troubleshooting guidance, and comparative advantages for advanced inflammation research.

• ATF4 Attenuates Doxorubicin-Induced Cardiotoxicity via H2S P

  2026-07-04

  This study demonstrates that ATF4 protects against doxorubicin-induced cardiomyopathy by enhancing hydrogen sulfide-mediated antioxidation, revealing a novel transcriptional mechanism involving CSE upregulation. These findings highlight ATF4 as a potential therapeutic target for mitigating the cardiotoxic effects of anthracycline chemotherapy in translational research models.

• Ibrexafungerp and Caspofungin in Treating Resistant Candida

  2026-07-03

  Wiederhold et al. demonstrate that ibrexafungerp, a first-in-class triterpenoid, exhibits potent in vitro and in vivo activity against fluconazole-resistant Candida auris, even with delayed therapy initiation. Their study benchmarks caspofungin as a comparator, reinforcing the clinical and research relevance of targeting β-(1,3)-D-glucan biosynthesis in antifungal strategies.

• Universal nPEC Method Optimizes Dual-Loaded Liposome Efficie

  2026-07-03

  This study introduces a robust nanoparticle exclusion chromatography (nPEC) method for accurately determining the encapsulation efficiency of both hydrophilic and lipophilic drugs in dual-loaded liposomes. The work addresses a key analytical challenge in combinatorial drug delivery, enabling reproducible and universally applicable assessments crucial for advanced therapeutic research.

• Caspofungin: Strategic Antifungal Innovation for Translation

  2026-07-02

  This thought-leadership article explores the mechanistic and translational power of Caspofungin, a lipopeptide antifungal drug, for research teams confronting azole-resistant Candida infections. By blending biological insight with protocol-driven guidance and evidence-backed context, it charts a path for investigators to optimize antifungal strategies and drive discovery in the evolving landscape of fungal therapeutics.

• Valemetostat (DS-3201): Transforming EZH2 Mutant Lymphoma Re

  2026-07-02

  This thought-leadership article explores the mechanistic and translational impact of Valemetostat (DS-3201), a first-in-class dual inhibitor targeting EZH1 and EZH2, on relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. Bridging mechanistic insights, experimental guidance, and strategic context, it positions Valemetostat as a pivotal tool for advancing epigenetic cancer therapy, while differentiating its discussion from standard product reviews.

• Aclacinomycin A: Mechanistic Insights and rDNA Damage Paradi

  2026-07-01

  Explore how Aclacinomycin A (Aclarubicin) uniquely disrupts ribosomal DNA integrity via topological stress, illuminating new assay strategies for apoptosis and genome stability. This article delivers in-depth mechanistic analysis and practical guidance distinct from prior workflows.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina

  2026-07-01

  This study identifies Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) as a potent ferroptosis inducer in triple-negative breast cancer (TNBC), acting through CUL3-mediated ubiquitination of MTDH. The findings establish a novel mechanistic pathway for ferroptosis regulation and highlight Gramine's translational potential in cancer biology research.

• Chlorin e6 Photosensitizer: Protocols for Advanced PDT Resea

  2026-06-30

  Chlorin e6 (Ce6) empowers both cancer therapy and antibacterial wound care with potent, light-triggered reactive oxygen species generation. Discover applied workflows, troubleshooting, and novel protocols—anchored by the latest innovation in silk fibroin nanofiber films and supported by APExBIO’s high-quality Ce6.

• Salinomycin: Polyether Ionophore Antibiotic for Advanced HCC

  2026-06-30

  Salinomycin stands out as a polyether ionophore antibiotic uniquely suited for hepatocellular carcinoma research, targeting cancer stem-like cells through Wnt/β-catenin pathway inhibition and apoptosis induction. Its robust activity profile and well-characterized mechanism make it a gold standard for mechanistic studies and drug response workflows.

• Oral CXCR4 Antagonist Mavorixafor in WHIM Syndrome: Phase 3

  2026-06-29

  Badolato et al.'s placebo-controlled phase 3 trial establishes the clinical utility of mavorixafor, a selective CXCR4 antagonist, for WHIM syndrome. The study demonstrates significant improvements in neutrophil and lymphocyte counts and a marked reduction in infection rates, highlighting a new therapeutic era for this rare immunodeficiency.

15750 records 1/1050 page Next 12345 下5页 Last page